Markt geschlossen· · GBp · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Incanthera PLC (AQSE:INC) has signed its first recurring revenue deal, supplying skincare creams to LED device maker iSmart Developments. It's a big step as the company shifts away from direct-to-consumer sales. Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has struck a deal with Mexico's largest private hospital network to pilot its Steriwave infection treatment. Trials showed a 40% drop in post-surgical infections. Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF, FRA:RR1) has moved its Uberaba project in Brazil into pre-feasibility work with Mosaic. Early economics already show a $916 million net p
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the erectile dysfunction gel Eroxon, has increased the size of its retail share offer after strong demand from investors. The retail offer closed on Friday, having attracted applications well beyond the...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the sexual health group behind the Eroxon erectile dysfunction gel, has begun a formal process that could see the sale of the business, or its assets. The move comes alongside a placing and subscription to raise approximately £1.6 million,...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has passed a series of operational milestones across its sexual health portfolio as it repositions for growth following a strategic review. The AIM-listed group behind Eroxon, the over-the-counter erectile dysfunction gel, appointed Market...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) said its stronger Eroxon Intense erectile dysfunction gel has been cleared for launch across the European Economic Area and UK, widening the group’s flagship consumer-health franchise. The clearance follows the completion of design, validation...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) chief executive Alex Duggan talked with Proactive about the company's new US commercial partnership for Eroxon and encouraging new clinical data for its women's sexual health product candidate, WSD4000. Duggan explained why Futura Medical...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the pharmaceutical group, said it intends to appeal a European Patent Office decision to revoke its patent for MED3000, the erectile dysfunction treatment sold as Eroxon. It will take the case to the EPO Technical Board of Appeal, a process...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) CEO Alex Duggan and head of R&D Ken James joined Proactive's Stephen Gunnion to discuss a new US commercial partnership for Eroxon and encouraging clinical data for women's sexual health candidate WSD4000. Duggan explained that Market Performance Group brings extensive consumer healthcare experience and will handle commercial execution, advertising, distribution and customer operations in the US. The arrangement shifts Futura away from a traditional licensing model, giving it greater control over brand strategy, promotional investment and produc
Metals One (AIM:MET1) is consolidating its South African gold strategy, with a deal that would lift its stake in Lions Bay Capital to 54.3%. The transaction implies a 237% unrealised gain on its investments so far. EnergyPathways (AIM:EPP) says the next twelve months are critical for its MESH energy storage project, with a value prize running into the billions. The company's targeting a final investment decision and commercial operation by 2031. Zephyr Energy (AIM:ZPHR) is pushing its Paradox Basin project towards first commercial production after strong drilling results in Utah. Revenue fell
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the erectile dysfunction gel Eroxon, said its experimental treatment for female sexual problems outperformed a placebo in studies. The company reported results on Tuesday from a home user test and a...
Powerhouse Energy Group (AIM:PHE) says CEO Paul Emmitt will step down in September, just as the company moves towards first commercial revenues. Non-executive chairman David Hitchcock will become executive chair until a new CEO is appointed, while Emmitt is expected to continue working with Engsolve on a technical consultancy basis. 2025 revenue jumped to £1.23 million, with losses narrowing too. Quantum Blockchain Technologies (AIM:QBT) says its Method C AI Oracle made real progress last year, including a 30% mining advantage in live testing. Losses widened slightly, but the company's since r
Share in Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) rose 19% to 0.6p after it ended its US partnership with consumer health giant Haleon PLC (LSE:HLN, NYSE:HLN) and lined up a new distributor for its erectile dysfunction treatment Eroxon. The group, which specialises in clinically...
Despite a challenging financial year, Futura Medical PLC (FAMDF) outlines a robust strategy for future growth with new product launches and strengthened partnerships.
MedPal AI plc (AIM:MPAL) has picked up a pharmacy facility in Runcorn for £310,000 from administrators. The site dispensed a million prescription items last year, worth around £10 million in turnover. Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) is shifting its Eroxon business from pure licensing toward a hybrid model with direct sales. It's also progressing two development projects, Eroxon Intense and the WSD4000 female sexual health platform. Solvonis Therapeutics PLC (LSE:SVNS) is pushing its alcohol use disorder drug SVN-001 into phase III trials rather than doing an early licensin
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind erectile dysfunction gel Eroxon, said it has refined its strategy and is evolving its commercial model following a comprehensive strategic review. In its full-year results statement, the told investors it...
Empire Metals (AIM:EEE, OTCQX:EPMLF) has wrapped up a big year in 2025, confirming one of the world's largest titanium resources at 2.2 billion tonnes in Western Australia. This year it's all about drilling, a scoping study, and a possible ASX listing. Caledonia Mining (AIM:CMCL, NYSE-A:CMCL, VFEX:CMCL) has had a cracking year — profit nearly tripled to $67.5 million as gold prices did the heavy lifting. Free cash flow jumped to $62 million, and the focus for 2026 is becoming a multi-mine producer. Quantum Helium (AIM:QHE) pulled in over $600,000 in oil sales last year from its Sagebrush P
The consumer healthcare company's new Intense formula showed stronger early effects than its existing product in a 223-person study Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the Eroxon erectile dysfunction gel, has reported positive results from...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has secured a US patent for Eroxon, protecting it until 2040. The grant triggers a $2.5 million milestone payment from Haleon. Ilika PLC (AIM:IKA, OTCQX:ILIKF, FRA:I8A) says its Goliath batteries passed live-fire safety tests with a UK defence agency. The results support potential use in defence applications like drones. Rome Resources Plc (AIM:RMR, FRA:33R) continues to hit high-grade tin at its Kalayi prospect in the Democratic Republic of Congo, extending mineralisation below the current resource. Drilling is nearly complete, with assays pend
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has secured a US notice of allowance for a continuation patent covering its erectile dysfunction treatment Eroxon and an in-development women’s sexual health product, extending protection until 2040. The consumer healthcare group, listed on...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) shares rose as much as 10% in early trading after the company said it expects to report revenue of £1.7 million for 2025, ahead of earlier guidance. The Surrey-based healthcare group, known for its erectile dysfunction treatment Eroxon, ended...
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.